# name
Tailoring formulations to patients in need: Experience with the
                paediatric formulation of artemether-lumefantrine (Coartem(R)
                Dispersible) for the treatment of P. falciparum malaria

# metadata.dc.description.abstract[].value
Specially created paediatric formulations have the potential to
                improve the acceptability, effectiveness and accuracy of dosing
                of artemisinin-based combination therapy (ACT) in young
                children, a patient group that is inherently vulnerable to
                malaria. Artemether-lumefantrine (AL) Dispersible is a
                paediatric formulation of AL that is specifically tailored for
                the treatment of children with uncomplicated Plasmodium
                falciparum malaria, offering benefits relating to efficacy,
                convenience and acceptance, accuracy of dosing, safety,
                sterility and stability, and a similar pharmacokinetic profile
                and bioequivalence to crushed and intact AL tablets. However,
                despite being the first paediatric antimalarial to meet World
                Health Organization (WHO) specifications for use in infants and
                children >/=5 kg, and its inclusion in WHO Guidelines, there
                are very few publications that focus on AL Dispersible. Based on
                a systematic review of the recent literature, this paper
                provides a comprehensive overview of clinical experience with AL
                Dispersible to date. A randomised, phase 3 study that compared
                the efficacy and safety of AL Dispersible with crushed AL
                tablets in 899 African children reported high PCR-corrected cure
                rates at day 28 (97.8% and 98.5% for dispersible and crushed
                tablets, respectively), and several sub-analyses of these data
                indicate that this activity is observed regardless of patient
                weight, food intake, and maximum plasma concentrations of
                artemether or its active metabolite dihydroartemisinin. These
                and other clinical data support the continued use of paediatric
                antimalarial formulations in all children <5 years of age
                with uncomplicated malaria, while accompanied by continued
                monitoring for the emergence of resistance.

# metadata.dc.relation.isformatof[].value
Reproducció del document publicat a:
                http://dx.doi.org/10.1128/AAC.00014-15

# metadata.dc.relation.ispartof[].value
Antimicrobial Agents and Chemotherapy, 2015, vol. 59, num. 8, p.
                4366-4374

# metadata.dc.rights[].value
(c)  American Society for Microbiology, 2015

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
Tailoring formulations to patients in need: Experience with the
                paediatric formulation of artemether-lumefantrine (Coartem(R)
                Dispersible) for the treatment of P. falciparum malaria